IMMUNOLOGY2026™ Conference Recordings For Attendees-Opposing Effects of Metoclopramide and Bromocriptine on Melanoma Response to Immune Checkpoint Blockade

Opposing Effects of Metoclopramide and Bromocriptine on Melanoma Response to Immune Checkpoint Blockade

Video Transcription

Video Summary

Researchers studied why immune checkpoint inhibitors work in only about half of advanced melanoma patients. Using genetically diverse mouse models, they identified a chromosome 13 “prolactin locus” linked to response. Validating this in Collaborative Cross mice showed prolactin influences tumor control, CD8 T-cell infiltration, and checkpoint inhibitor efficacy. Drugs that lower prolactin signaling, like bromocriptine, reduced treatment benefit, while drugs that raise prolactin, like metoclopramide, improved survival and immune activation. Mechanistically, metoclopramide boosted T-cell activation, MHC expression, and anti-tumor macrophage markers, suggesting prolactin modulation could enhance melanoma immunotherapy.

Meta Tag

Date April 16, 2026 4:30 PM - 4:45 PM

Room 205

Session Immune Checkpoints and Beyond I

Speaker Mark Gregory

Track Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

Year 2026

Keywords

melanoma immunotherapy

immune checkpoint inhibitors

prolactin locus

CD8 T-cell infiltration

metoclopramide

April 16, 2026 4:30 PM - 4:45 PM

205

Immune Checkpoints and Beyond I

Mark Gregory

Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

2026